<DOC>
	<DOCNO>NCT02182232</DOCNO>
	<brief_summary>The primary objective trial determine MTD BIBF 1120 combination carboplatin paclitaxel , pharmacokinetics objective response treatment</brief_summary>
	<brief_title>A Dose Escalation Study BIBF 1120 Together With Paclitaxel Carboplatin Patients With Advanced Stage Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Male female patient histologically cytologically confirm Stage IIIB ( include pleural effusion ) , IV recurrent NSCLC 2 . Bidimensionally measurable disease one technique ( CT , MRI , Xray ) 3 . Age 18 year old 4 . Life expectancy least three ( 3 ) month 5 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 6 . Written inform consent consistent ICHGCP guideline 1 . Prior treatment NSCLC include chemotherapy , biologic response modifier therapy , investigational drug 2 . Participation another clinical study within past four week start therapy concomitantly study 3 . Active brain metastasis ( stable &lt; 28 day , symptomatic , require concurrent steroid antiepileptic therapy ) 4 . Centrally locate tumor radiologic evidence ( CT MRI ) local invasion major blood vessel 5 . Cavitary necrotic tumor 6 . Sanguinous pleural effusion due disease pericardial effusion suspicious disease 7 . Radiotherapy area measurable disease ( unless disease progression document follow completion therapy ) 8 . Radiotherapy within 4 week precede Day 0 9 . Other active malignancy diagnose within past 3 year ( nonmelanomatous skin cancer ) 10 . Gastrointestinal abnormality would interfere intake absorption study drug , requirement intravenous alimentation , prior surgical procedure affect absorption , treatment peptic ulcer disease within last 6 month , active gastrointestinal bleeding unrelated cancer ( evidence either hematemesis , hematochezia , melena past 3 month without endoscopic document resolution ) , malabsorption syndrome 11 . Significant cardiovascular disease ( i.e. , uncontrolled hypertension , myocardial infarction within 6 month , unstable angina , serious cardiac arrhythmia , ≥NYHA Grade 2 congestive heart failure ) 12 . History hemorrhagic thrombotic event ( include transient ischemic attack ) past 12 month 13 . Clinically significant hemoptysis ( 1 teaspoon ) past 3 month 14 . Concurrent therapeutic anticoagulation ( except heparin flush need maintenance indwell intravenous device ) antiplatelet therapy ( except chronic lowdose daily aspirin &lt; 325 mg ) 15 . Known hypersensitivity paclitaxel , carboplatin , excipients include Cremophor® ( polyoxyethylated castor oil ) 16 . Absolute neutrophil count ( ANC ) ≤1,500/μl , platelet count ≤100,000/μl , hemoglobin &lt; 9 gm/dL 17 . Total bilirubin &gt; 1.5 mg/dL ( 26 μmol/L , SI Unit equivalent ) , alanine amino transferase ( ALT ) and/or aspartate amino transferase ( AST ) ≥1.5 X ULN , 18 . Serum creatinine &gt; 1.5 mg/dL ( &gt; 132 μmol/L , SI Unit equivalent ) 19 . Persistent hematuria proteinuria ( trace ) 20 . Women men sexually active unwilling use medically acceptable method contraception 21 . Pregnancy breastfeed 22 . Known suspect active alcohol drug abuse 23 . Patients unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>